GW&K Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

GW&K Investment Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68K	Hold	255	–	–	﹤0.01%	536
2026 Q1	$58K	Buy	255 +29	+13%	+$6.5K	﹤0.01%	534
2025 Q4	$48K	Buy	226 +97	+75%	+$20K	﹤0.01%	559
2025 Q3	$26K	Buy	129 +28	+28%	+$5.22K	﹤0.01%	672
2025 Q2	$17K	Buy	+101	New	+$16.5K	﹤0.01%	745

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

GW&K Investment Management's ASND Position: Q2 2026 in Review

GW&K Investment Management held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 255 shares worth $68K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

GW&K Investment Management first reported a position in ASND in Q2 2025 and has held it in 5 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

GW&K Investment Management held 255 shares of Ascendis Pharma A/S worth $68K as of Q2 2026.
GW&K Investment Management left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #536 holding.
GW&K Investment Management first reported a position in Ascendis Pharma A/S in Q2 2025 and has held it in 5 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.